Date : 21 April 2026

| Companies | Headquarters | Deep Brain Stimulation Devices |
| Medtronic plc. | Minneapolis, U.S. | Percept PC and Activa |
| Abbott Laboratories | Abbott Park, U.S. | Inficity DBS System and Liberta RC |
| Boston Scientific | Marlborough, U.S. | Vercise Genus, Vecises PC, and Vercise Gevia |
| Beijing PINS Medical | Beijing, China | PINS DBS |
| Aleva Neurotherapeutics | Lausanne, Switzerland | Aleva directSTIM |
| SceneRay Corporation | Suzhou, China | SceneRay DBS System |
| Newronika S.p.A. | Milan, Italy | AlphaDBS System |
| Renishaw plc | Wotton-under-Edge, UK | Neuromata |
| NeuroPace, Inc. | Mountain View, U.S. | RNS System |
| Functional Neuromodulation | Toronto, Canada | Vercise |
R&D
Clinical Trials and Regulatory Approvals
Packaging and Serialization
Distribution to Hospitals, Pharmacies
Patient Support and Services
The global deep brain stimulation devices market size was estimated at USD 2.15 billion in 2025 and is predicted to increase from USD 2.34 billion in 2026 to approximately USD 5.04 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035.

Speak with a healthcare analyst about your research, consulting, or platform needs.